Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
SEEGENE
FOCUS DIAGNOSTICS, INC.

Immunoassay Control Monitors 54 Analytes Including Vitamin D

By Labmedica International staff writers
Posted on 03 Jan 2012
An immunoassay premium plus control is designed to monitor the accuracy and precision of up to 54 analytes including 25-OH Vitamin D and 1-25(OH)2 Vitamin D.

Specific target values are also provided for a wide range of fertility hormones, thyroid hormones, steroid hormones, kidney function tests, therapeutic drugs, and tumor markers. The inclusion of routinely run tumor markers and parameters such as intact parathyroid hormone (PTH) allows quality control practices to be simplified by dramatically reducing the number of controls used in the laboratory with the added benefit of cost and time savings.

The Acusera immunoassay premium plus control is being offered by Randox (Crumlin, United Kingdom). It has a shelf life of up to four years and is suitable for long-term quality control (QC) monitoring. It can significantly reduce the costs and problems associated with changing lot numbers.

In addition to low Vitamin B12 levels, the Randox Immunoassay Premium and Premium Plus controls contain ultra low levels of ferritin and thyroid stimulating hormone (TSH) as well as other vitamins. The control also contains many of the routinely run tumor markers including alpha-fetoprotein (AFP), CA15-3, CA19-9, CA-125, CEA, prostate specific antigen (PSA), and Free-PSA.

Vitamin D can also be found in the Randox RIQAS Immunoassay EQA program. RIQAS (Randox International Quality Assessment Scheme) is a large global EQA scheme with more than 20,000 participants in over 100 countries worldwide.

Related Links:

Randox



GREINER-BIO-ONE
PURITAN MEDICAL
ADVANCED INSTRUMENTS
BioConferenceLive

Channels

Clinical Chemistry

view channel
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).

Pregnancy Tests Evaluated During Early Gravidity

The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.... Read more

Genetic Tests

view channel
Image: The Quant-iT PicoGreen dsDNA Assay Kit (Photo courtesy of Invitrogen).

Blood Test Provides Rapid Method of Detecting Solid Cancers

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing detection methods have insufficient sensitivity or patient coverage for broad clinical applicability.... Read more

Pathology

view channel
Image: Micrograph showing prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Zephron).

New Test Could Accurately Predict Prostate Cancer Recurrence

A test based on genetic signature and tumor oxygen levels, which boost the test’s accuracy, can predict whether a man is at high risk of prostate cancer recurrence. Prostate cancer is the most common... Read more

Industry News

view channel

Roche and Hitachi Renew Alliance in Diagnostics

Roche (Basel, Switzerland) and Hitachi (Tokyo, Japan) have renewed their alliance in the diagnostics business by 10-years for the joint development and manufacture of the next generation of instruments and workflow automation solutions for medical laboratories. The renewed alliance marks a significant milestone towards... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.